Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2005

Mozzetti Simona, Ferlini Cristiano, Concolino Paola, Filippetti Flavia, Raspaglio Giuseppina, Prislei Silvia, Gallo Daniela, Martinelli Enrica, Ranelletti Franco Oreste, Ferrandina Gabriella, Scambia Giovanni

Abstract excerpt

The vast majority of women with advanced ovarian cancer will ultimately relapse and develop a drug-resistant disease with an overall 5-year survival of <50%. Unfortunately, the mechanisms of drug resistance actually operating in patients are still unknown. To address this issue, in 41 patients affected by advanced ovarian cancer the three main mechanisms of paclitaxel resistance were investigated: overexpression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Ovarian Neoplasms

Share to Paclitaxel

Share to Point Mutation

Share to Protein Isoforms

Share to Tubulin

Share to Up-Regulation

Source

Open in PubMed

Identifiers

PMID: 15671559

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.PMID 15671559Read ↗

Class III β-Tubulin Overexpression Is a Prominent Mechanism of Paclitaxel Resistance in Ovarian Cancer PatientsSemantic proximity Read ↗

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.Semantic proximity Read ↗

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.Semantic proximity Read ↗

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Semantic proximity Read ↗

Key genes and molecular mechanisms related to Paclitaxel ResistanceSemantic proximity Read ↗

Taxol Resistance Among the Different Histological Subtypes of Ovarian Cancer May Be Associated With the Expression of Class III β-TubulinSemantic proximity Read ↗

Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.Semantic proximity Read ↗

Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic ManipulationSemantic proximity Read ↗

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.Semantic proximity Read ↗

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionSemantic proximity Read ↗

Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.Semantic proximity Read ↗

Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation TaxanesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.